BBC / ETFis Series Trust I - Virtus Biotech Clinical Trials ETF - Institutionelt ejerskab - Købere

ETFis Series Trust I - Virtus Biotech Clinical Trials ETF
US ˙ ARCA

Institutionelt og fondsejerskab - Købere

Større indehavere, der har åbnet nye stillinger i ETFis Series Trust I - Virtus Biotech Clinical Trials ETF, omfatter Militia Capital Management LLC, Quantinno Capital Management LP, Aurora Private Wealth, Inc., Global Assets Advisory, LLC, og Blair William & Co/il .

Denne side viser ændringer i ejerskabsstrukturen ved at notere institutioner, fonde og større aktionærer, der har øget deres beholdning eller åbnet nye positioner i den seneste rapporteringsperiode. Grønne rækker angiver nye positioner. Klik på linket ikon for at se den fulde transaktionshistorik.

Opgrader for at låse op for premium-data.

Fil dato Kilde Investor Type Gennemsnitlig pris
(Øst)
Aktier Δ Aktier
(%)
Rapporteret
Værdi
($1000)
Δ Værdi
(%)
Port Alloc
(%)
2026-05-01 13F Global Assets Advisory, LLC 2.000 104
2026-05-15 13F Quantinno Capital Management LP 19.383 807
2026-05-08 13F Blair William & Co/il 28 1
2026-05-13 13F Militia Capital Management LLC 45.663 1.901
2026-05-06 13F LPL Financial LLC 12.432 0,95 517 9,07
2026-05-15 13F Susquehanna International Group, Llp 52.053 137,01 2.167 156,03
2026-05-06 13F Kera Capital Partners, Inc. 89.364 5,17 3.720 7,18
2026-04-16 13F Aurora Private Wealth, Inc. 11.376 0
2026-05-15 13F Flow Traders U.s. Llc 10.378 0
How Much do you Like Fintel?
Please share your opinion of our service!
Excellent Bad
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista